Abstract | OBJECTIVES: METHODS: RESULTS: At baseline and 4 months, 58.7% and 73.3% of patients were receiving optimal medical therapy, respectively. These patients had no differences in important parameters such as left ventricular ejection fraction and left ventricular volumes. In a multivariable Cox model, optimal medical therapy at baseline was associated with a lower all-cause mortality (hazard ratio, 0.78; 95% confidence interval, 0.66-0.91; P = .001). When landmarked at 4 months, optimal medical therapy was also associated with a lower all-cause mortality (hazard ratio, 0.82; 95% confidence interval, 0.62-0.99; P = .04). There was no interaction between the benefit of optimal medical therapy and treatment allocation. CONCLUSIONS: Optimal medical therapy was associated with improved long-term survival and lower cardiovascular mortality in patients with ischemic cardiomyopathy and should be strongly recommended.
|
Authors | Pedro S Farsky, Jennifer White, Hussein R Al-Khalidi, Carla A Sueta, Jean L Rouleau, Julio A Panza, Eric J Velazquez, Christopher M O'Connor, Working Group and Surgical Treatment for Ischemic Heart Failure Trial Investigators |
Journal | The Journal of thoracic and cardiovascular surgery
(J Thorac Cardiovasc Surg)
Vol. 164
Issue 6
Pg. 1890-1899.e4
(12 2022)
ISSN: 1097-685X [Electronic] United States |
PMID | 33610365
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2021 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved. |
Topics |
- Humans
- Stroke Volume
- Ventricular Function, Left
- Coronary Artery Disease
(surgery)
- Myocardial Ischemia
(complications, therapy)
- Heart Failure
(surgery)
- Cardiomyopathies
(drug therapy, complications)
- Treatment Outcome
- Ventricular Dysfunction, Left
|